Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer

Lung Cancer

Volumn 40, Issue 3, 2003, Pages 339-342

  Okamoto, Isamu ^a   Fujii, Kazuhiko ^a   Matsumoto, Mitsuhiro ^a   Terasaki, Yasuhiro ^a   Kihara, Nanae ^a   Kohrogi, Hirotsugu ^a   Suga, Moritaka ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Diffuse alveolar damage; EGFR tyrosine kinase inhibitor; Pulmonary toxicity; ZD1839 (Iressa)

Indexed keywords

GEFITINIB; METHYLPREDNISOLONE;

AGED; ARTICLE; CANCER MORTALITY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; DRUG MEGADOSE; DYSPNEA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG TOXICITY; MALE; PRIORITY JOURNAL; RESPIRATORY FAILURE; SIDE EFFECT; STEROID THERAPY; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 0038021573     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00043-6     Document Type: Article

References (14)

1. Arteaga C.L., Johnson D.H. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr. Opin. Oncol. 13:2001;491-498.
2. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7:2001;2958-2970.
3. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20:2002;4292-4302.
4. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 20:2002;2240-2250.
5. Herbst R.S., Maddox A.M., Rothenberg M.L., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20:2002;3815-3825.
6. Fukuoka M., Yano S., Giaccone G., et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small cell lung cancer (IDEAL1). Proc. Am. Soc. Clin. Oncol. 21:2002;298a.
7. Kris M.G., Natale R.B., Herbst R.S., et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol. 21:2002;292a.
8. Foucher P., Biour M., Blyac J.P., et al. Drugs that may injure the respiratory system. Eur. Respir. J. 10:1997;265-279.
9. Katzenstein A.L., Bloor C.M., Leibow A.A. Diffuse alveolar damage - the role of oxygen, shock, and related factors. Am. J. Pathol. 85:1976;209-228.
10. Blennerhassett J.B. Shock lung and diffuse alveolar damage pathological and pathogenetic considerations. Pathology. 17:1985;239-247.
11. Madtes D.K., Busby H.K., Strandjord T.P., Clark J.G. Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats. Am. J. Respir. Cell. Mol. Biol. 11:1994;540-551.
12. Madtes D.K., Rubenfeld G., Klima L.D., et al. Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care. Med. 158:1998;424-430.
13. Hardie W.D., Prows D.R., Leikauf G.D., Korfhagen T.R. Attenuation of acute lung injury in transgenic mice expressing human transforming growth factor-alpha. Am. J. Physiol. 277:1999;1045-1050.
14. Hardie W.D., Prows D.R., Piljan-Gentle A., et al. Dose-related protection from nickel-induced lung injury in transgenic mice expressing human transforming growth factor-alpha. Am. J. Respir. Cell. Mol. Biol. 26:2002;430-437.